Clinical Trials on Neuroendocrine Tumours (NET) in Spain

Total 1038 results

Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
RayzeBio, Inc.

Active, not recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Neuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NET

Canada, Spain, United States, Netherlands, Belgium, France, Brazil
Novartis Pharmaceuticals

Completed

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4)

Neuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung Origin

United States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
Grupo Espanol de Tumores Neuroendocrinos

Active, not recruiting

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Neuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

Spain
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Novartis Pharmaceuticals

Completed

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Pancreatic Neuroendocrine Tumors (pNET)

France, Spain, Belgium, Germany, Italy, United Kingdom, Austria, Netherlands, United States
Grupo Espanol de Tumores Neuroendocrinos
Pfizer; Apices Soluciones S.L.

Completed

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib (RESUNET)

Pancreatic Neuroendocrine Tumour Metastatic

Spain
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors (pNET)

United Kingdom, Spain, Netherlands, Italy, Russian Federation, France, Switzerland, United States
Grupo Espanol de Tumores Neuroendocrinos

Completed

Pazopanib as Single Agent in Advanced NETs

Advanced/Metastatic Neuroendocrine Tumors

Spain
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Gastro-enteropancreatic Neuroendocrine Tumor

Spain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

United States, Spain, Germany, Japan
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Pheochromocytoma | Paraganglioma | Gastroenteropancreatic Neuroendocrine Tumors

United States, Spain, France, Poland, United Kingdom
Grupo Espanol de Tumores Neuroendocrinos

Recruiting

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor (NUTRIGETNE)

Gastroenteropancreatic Neuroendocrine Tumor

Spain
Camurus AB

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Gastro-enteropancreatic Neuroendocrine Tumor

United States, Belgium, Spain, Netherlands, France, Germany, Israel, Italy, Canada, Australia, Romania, Hungary
Grupo Espanol de Tumores Neuroendocrinos

Completed

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (PALBONET)

Pancreatic Neuroendocrine Cancer

Spain
Advanced Accelerator Applications

Active, not recruiting

Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS)

Neuroendocrine Tumors

United Kingdom, Portugal, Spain, France, United States
Ipsen

Completed

Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours (QUALINETS)

Gastrointestinal Neuroendocrine Tumours

Spain, Portugal
AI Labs Group S.L
Hospital de Basurto; Osakidetza; Hospital de Cruces; Servicio Vasco de Salud Osakidetza...

Recruiting

Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma (LEGIT_MC_EVCDA)

Melanoma | Melanoma, Skin

Spain
Philogen S.p.A.
Immatics Biotechnologies GmbH

Terminated

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Merkel Cell Carcinoma

Germany, Austria, Denmark, France, Spain, United Kingdom
Sociedad Española de Oncología Quirúrgica
Sysmex España

Unknown

Validation of Ferromagnetic Tracer in Melanoma Sentinel Node (IMINEM)

Sentinel Lymph Node | Melanoma Stage

Spain
Hospital Universitario Virgen Macarena

Recruiting

Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT)

Melanoma Stage III

Spain
Hospital Universitari de Bellvitge

Recruiting

Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery. (TNE-IDC-COLE)

Biliary Stones | Midgut Carcinoid Tumor

Spain
Ipsen

Terminated

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)

Pancreatic Neuroendocrine Tumor

Spain, Portugal
Hoffmann-La Roche

Withdrawn

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)

Medullary Thyroid Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos
Roche Pharma AG; Ipsen

Active, not recruiting

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)

Adenocarcinoma | Neuroendocrine Tumor | Pheochromocytoma | Paraganglioma | Anaplastic Thyroid Cancer

Spain
Aduro Biotech, Inc.

Terminated

Safety of ADU-1604 in Adults With Metastatic Melanoma

Metastatic Melanoma

Spain, France
Pfizer

Completed

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Well-differentiated Pancreatic Neuroendocrine Tumor

United States, China, Czechia, India, Japan, South Africa, Slovakia, France, Norway, Romania, Australia, Belgium, Hungary, Italy, Spain
eTheRNA immunotherapies

Terminated

Safety of Intranodal ECI-006 in Melanoma Patients

Melanoma

Belgium, Spain
Ipsen

Terminated

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (SPINET)

Neuroendocrine Tumors in Lung

Canada, United States, Germany, France, United Kingdom, Netherlands, Spain, Denmark, Italy, Austria, Poland
4SC AG

Completed

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
Grupo Espanol de Tumores Neuroendocrinos

Completed

Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria (CRIPNET)

Pancreatic Neuroendocrine Tumors

Spain
ITM Solucin GmbH

Recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

Neuroendocrine Tumors

United States, United Kingdom, Australia, France, Italy, Netherlands, Spain, Germany, Sweden, India
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Pancreatic Neoplasms | Neuroendocrine Tumor | Neuroendocrine Carcinoma | Islet Cell Carcinoma

United States, Canada, Spain, Argentina, Germany, Belgium, Italy, France, Sweden, Australia, Netherlands
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Spain, Switzerland, Germany, United States, Netherlands
GlaxoSmithKline

Terminated

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Melanoma

Spain, France
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Neoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)

France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary
Grupo Espanol de Tumores Neuroendocrinos

Completed

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE)

Neuroendocrine Tumors | Neuroendocrine Neoplasm of Lung

Spain
Achilles Therapeutics UK Limited

Recruiting

ATL001 in Patients With Metastatic or Recurrent Melanoma

Melanoma

Spain, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Highlight Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)

Melanoma

Spain, France
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

United States, Australia, Canada, France, Italy, New Zealand, Spain, Sweden
Anna Cruceta

Unknown

Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer (SENTINELSEEK)

Melanoma | Breast Cancer | Head Cancer | Neck Cancer

Spain
Hospital Universitario Virgen de la Arrixaca

Recruiting

Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.

Cutaneous Melanoma | Anatomical Pathological Condition

Spain

Clinical Trials on Neuroendocrine Tumours (NET) in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations